JP2004521894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521894A5 JP2004521894A5 JP2002559067A JP2002559067A JP2004521894A5 JP 2004521894 A5 JP2004521894 A5 JP 2004521894A5 JP 2002559067 A JP2002559067 A JP 2002559067A JP 2002559067 A JP2002559067 A JP 2002559067A JP 2004521894 A5 JP2004521894 A5 JP 2004521894A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- aryl
- coor
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 248
- 125000003118 aryl group Chemical group 0.000 claims 90
- 125000003545 alkoxy group Chemical group 0.000 claims 44
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 125000001424 substituent group Chemical group 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 36
- 239000001257 hydrogen Substances 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 34
- 239000011780 sodium chloride Substances 0.000 claims 34
- 239000012453 solvate Substances 0.000 claims 34
- -1 R 7 -Benzyl Chemical group 0.000 claims 27
- 125000005843 halogen group Chemical class 0.000 claims 24
- 125000001072 heteroaryl group Chemical class 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 125000002947 alkylene group Chemical group 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrugs Drugs 0.000 claims 16
- 230000001225 therapeutic Effects 0.000 claims 16
- 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000004432 carbon atoms Chemical group C* 0.000 claims 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000002541 furyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000002883 imidazolyl group Chemical group 0.000 claims 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000000168 pyrrolyl group Chemical group 0.000 claims 10
- 125000003003 spiro group Chemical group 0.000 claims 10
- 235000003702 sterols Nutrition 0.000 claims 10
- 150000003432 sterols Chemical class 0.000 claims 10
- 125000000335 thiazolyl group Chemical group 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 10
- 239000003613 bile acid Substances 0.000 claims 9
- 239000003352 sequestering agent Substances 0.000 claims 9
- URSPTJYSBTXILH-UHFFFAOYSA-N 1-methylidenepiperazin-1-ium-4-ide Chemical group C=[N+]1CC[N-]CC1 URSPTJYSBTXILH-UHFFFAOYSA-N 0.000 claims 8
- 125000004450 alkenylene group Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims 8
- 125000002757 morpholinyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 238000010521 absorption reaction Methods 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical class 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical class 0.000 claims 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000000051 benzyloxy group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 125000005879 dioxolanyl group Chemical group 0.000 claims 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 4
- 201000011528 vascular disease Diseases 0.000 claims 4
- 229940107161 Cholesterol Drugs 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 210000002381 Plasma Anatomy 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 claims 2
- 229920001268 Cholestyramine Polymers 0.000 claims 2
- 229920002911 Colestipol Polymers 0.000 claims 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N Colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 2
- 125000000676 alkoxyimino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005336 allyloxy group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical class O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims 2
- 230000037348 biosynthesis Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 229960002604 colestipol Drugs 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920000728 polyester Polymers 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;N-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229920002905 Colesevelam Polymers 0.000 claims 1
- 229960000674 Colesevelam hydrochloride Drugs 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N Probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 102100011656 SLC10A2 Human genes 0.000 claims 1
- 101710036999 SLC10A2 Proteins 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 235000002378 plant sterols Nutrition 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- 0 CCCCC1C(C(C2)C2*2=CC2)C(C)*(C)C1C Chemical compound CCCCC1C(C(C2)C2*2=CC2)C(C)*(C)C1C 0.000 description 3
- GOPUCFKUFOFEIC-UHFFFAOYSA-N CC1OCCN1 Chemical compound CC1OCCN1 GOPUCFKUFOFEIC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26460001P | 2001-01-26 | 2001-01-26 | |
| US32384201P | 2001-09-21 | 2001-09-21 | |
| PCT/US2002/002010 WO2002058733A2 (en) | 2001-01-26 | 2002-01-25 | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521894A JP2004521894A (ja) | 2004-07-22 |
| JP2004521894A5 true JP2004521894A5 (US07560449-20090714-C00027.png) | 2006-01-19 |
Family
ID=26950649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559067A Pending JP2004521894A (ja) | 2001-01-26 | 2002-01-25 | 胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療 |
Country Status (16)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2290562T3 (es) * | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
| EP1429756B1 (en) * | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| WO2004028470A2 (en) * | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| US7208486B2 (en) * | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2004094608A2 (en) * | 2003-04-18 | 2004-11-04 | Curagen Corporation | Human procolipase like nucleic acids and polypeptides and their methods of use threof |
| US20070238717A1 (en) * | 2003-10-21 | 2007-10-11 | Johns Hopkins University | Neuroprotection with Beta-Lactam Compounds |
| WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| WO2005046662A2 (en) | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
| US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| EP1750862B1 (en) * | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| BRPI0612908A2 (pt) * | 2005-07-18 | 2010-12-07 | Reliant Phamaceuticals Inc | composições farmacêuticas compreendendo inibidores de absorção de colesterol à base de azetidinona e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
| WO2011075539A2 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
| TR201005327A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Sinerjik farmasötik formülasyonlar. |
| JP2017517550A (ja) | 2014-06-13 | 2017-06-29 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニル製剤 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1286A (en) * | 1839-08-13 | Richard else | ||
| US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
| US3108097A (en) * | 1963-10-22 | Ehnojs | ||
| NL108640C (US07560449-20090714-C00027.png) * | 1958-05-07 | |||
| NL127065C (US07560449-20090714-C00027.png) * | 1964-04-22 | |||
| NL137318C (US07560449-20090714-C00027.png) * | 1964-06-09 | |||
| US3716583A (en) * | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
| US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| DE2230383C3 (de) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
| US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
| US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
| US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
| US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
| US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
| JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
| US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
| US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
| US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
| US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
| US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
| FR2403078A1 (fr) * | 1977-09-19 | 1979-04-13 | Lafon Labor | Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic |
| IT1157365B (it) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
| US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
| US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
| US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DE3107100A1 (de) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
| US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
| US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
| US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
| US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
| US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
| US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
| US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
| CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
| US4614614A (en) * | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
| US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
| WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
| US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
| US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
| US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
| FR2561916B1 (fr) * | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
| US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
| US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
| US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
| US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
| US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| DE3787815T2 (de) * | 1986-02-19 | 1994-03-24 | Sanraku Inc | Azetidinonderivate. |
| GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
| FR2598146B1 (fr) * | 1986-04-30 | 1989-01-20 | Rech Ind | Nouveau procede de preparation de fibrates. |
| DE3621861A1 (de) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen |
| FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
| US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
| US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
| US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
| JPS63156788A (ja) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | 光学活性アゼチジノン類 |
| US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| EP0288973B1 (en) * | 1987-04-28 | 1993-01-13 | Fujisawa Astra Ltd. | Benzothiazolinone derivatives, their production and pharmaceutical composition |
| US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
| US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
| US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| DE3807895A1 (de) * | 1988-03-10 | 1989-09-21 | Knoll Ag | Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker |
| GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
| US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
| US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
| US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
| US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| FR2640621B1 (fr) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| JPH03108490A (ja) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | フォスフォリパーゼａ↓２阻害物質 |
| US5021461A (en) * | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
| US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
| US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
| US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| JP2640986B2 (ja) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法 |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| JPH10501811A (ja) * | 1994-06-20 | 1998-02-17 | シェーリング コーポレイション | 低コレステロール化剤として有用な置換アゼチジノン化合物 |
| JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| JP2002533411A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための組み合わせ |
| PE20020453A1 (es) * | 2000-09-27 | 2002-06-06 | Merck & Co Inc | Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| ATE349425T1 (de) * | 2000-12-21 | 2007-01-15 | Sanofi Aventis Deutschland | Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen |
| IL156548A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| CZ20032031A3 (cs) * | 2001-01-26 | 2003-12-17 | Schering Corporation | Farmaceutický prostředek |
| ES2290562T3 (es) * | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
| PL205343B1 (pl) * | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu |
| US20020183305A1 (en) * | 2001-01-26 | 2002-12-05 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| JP2004521124A (ja) * | 2001-02-09 | 2004-07-15 | メルク エンド カムパニー インコーポレーテッド | 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類 |
| WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
-
2002
- 2002-01-25 DE DE60221798T patent/DE60221798T2/de not_active Expired - Fee Related
- 2002-01-25 EP EP02707556A patent/EP1363668B1/en not_active Expired - Lifetime
- 2002-01-25 MX MXPA03006631A patent/MXPA03006631A/es active IP Right Grant
- 2002-01-25 EP EP07003151A patent/EP1785144A3/en not_active Withdrawn
- 2002-01-25 AT AT02707556T patent/ATE369851T1/de not_active IP Right Cessation
- 2002-01-25 JP JP2002559067A patent/JP2004521894A/ja active Pending
- 2002-01-25 AR ARP020100267A patent/AR035739A1/es not_active Application Discontinuation
- 2002-01-25 WO PCT/US2002/002010 patent/WO2002058733A2/en active IP Right Grant
- 2002-01-25 PT PT02707556T patent/PT1363668E/pt unknown
- 2002-01-25 SI SI200230601T patent/SI1363668T1/sl unknown
- 2002-01-25 DK DK02707556T patent/DK1363668T3/da active
- 2002-01-25 TW TW096128030A patent/TW200744638A/zh unknown
- 2002-01-25 CA CA002434033A patent/CA2434033A1/en not_active Abandoned
- 2002-01-25 AU AU2002241956A patent/AU2002241956A1/en not_active Abandoned
- 2002-01-25 US US10/057,534 patent/US20030053981A1/en not_active Abandoned
- 2002-01-25 ES ES02707556T patent/ES2287250T3/es not_active Expired - Lifetime
-
2007
- 2007-10-08 CY CY20071101283T patent/CY1106915T1/el unknown
-
2008
- 2008-06-11 US US12/136,985 patent/US20080261942A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521894A5 (US07560449-20090714-C00027.png) | ||
| JP2004521893A5 (US07560449-20090714-C00027.png) | ||
| JP2004532186A5 (US07560449-20090714-C00027.png) | ||
| JP2004517916A5 (US07560449-20090714-C00027.png) | ||
| RU2003126184A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов | |
| RU2007131955A (ru) | Применение замещенных азетидинонов для лечения ситостеролемии | |
| JP3992728B2 (ja) | コレステロール生合成阻害剤およびβ−ラクタムコレステロール吸収阻害剤の組合せ | |
| AU2003261217B2 (en) | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent | |
| JP2004532868A5 (US07560449-20090714-C00027.png) | ||
| JP2005504092A5 (US07560449-20090714-C00027.png) | ||
| JP2004517920A5 (US07560449-20090714-C00027.png) | ||
| US20080166318A1 (en) | Methods and therapeutic combinations for the treatment of demyelination | |
| JP4875491B2 (ja) | メトホルミンとスタチンとの組み合わせを含む医薬組成物 | |
| WO2002058733B1 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
| JP2005533810A (ja) | 新規な抗コレステロール組成物及びその使用方法 | |
| RU2003126185A (ru) | Комбинации ингибитора (ингибиторов) всасывания стерина с модификатором (модификаторами) крови, предназначенные для лечения патологических состояний сосудов | |
| CA2460340A1 (en) | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | |
| JP2002508320A5 (US07560449-20090714-C00027.png) | ||
| RU2005121909A (ru) | Профилактика и лечение болезни альцгеймера | |
| ZA200102230B (en) | Method for preventing or delaying catheter-based revascularization. | |
| WO2002047678A1 (fr) | Agents hypolipemiants | |
| WO2011002424A2 (en) | Solubility and stability enchancing pharmaceutical formulation |
